Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021.

被引：0
|
作者：
Vardell, Victoria
Tantravahi, Srinivas Kiran
机构：
[1] Univ Utah, Dept Hematol & Hematol Malignancies, Salt Lake City, UT USA
[2] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11187
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
    DeAngelo, D. J.
    BLOOD CANCER JOURNAL, 2012, 2 : e95 - e95
  • [42] Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China
    Jiang, Qian
    Gale, Robert Peter
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (07) : 1549 - 1555
  • [43] Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy
    Berman, Ellin
    Druker, Brian J.
    Burwick, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) : 1250 - +
  • [44] More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia
    Haddad, Fadi
    Sasaki, Koji
    Issa, Ghayas C.
    Kim, Kunhwa
    Skinner, Jeffrey
    Dellasala, Sara E.
    Alvarado, Yesid
    Ferrajoli, Alessandra
    Kadia, Tapan M.
    Yilmaz, Musa
    Pemmaraju, Naveen
    Garcia-Manero, Guillermo
    Pierce, Sherry A.
    Jabbour, Elias
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 3897 - 3899
  • [45] REAL-WORLD TARGETED LITERATURE REVIEW OF INTOLERANCE WITH TYROSINE KINASE INHIBITOR TREATMENT FOR CHRONIC MYELOID LEUKEMIA
    Jadhav, K.
    Damon, A.
    Yang, D.
    Latremouille-Viau, D.
    Yang, D.
    Guerin, A.
    Sadek, I
    VALUE IN HEALTH, 2023, 26 (06) : S400 - S400
  • [46] Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma
    Katzel, Jed A.
    Lee-Ma, Annette
    Vesole, David H.
    ANTI-CANCER DRUGS, 2015, 26 (08) : 907 - 909
  • [47] Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views
    Tromp, Vashti N. M. F.
    Timmers, Lonneke
    Koningen, Leanne
    Janssen, Jeroen J. W. M.
    Westerweel, Peter E.
    Geelen, Inge G. P.
    de Jong, Jan
    Beckeringh, Jan J.
    Boons, Christel C. L. M.
    Hugtenburg, Jacqueline G.
    LEUKEMIA & LYMPHOMA, 2021, 62 (03) : 649 - 658
  • [48] Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia
    Hill, Brittany G.
    Kota, Vamsi K.
    Khoury, Hanna Jean
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (07) : 765 - 770
  • [49] Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia
    McGarry, Lisa J.
    Chen, Yaozhu J.
    Divino, Victoria
    Pokras, Shibani
    Taylor, Catherine R.
    Munakata, Julie
    Nieset, Christopher C.
    Huang, Hui
    Jabbour, Elias
    Malone, Daniel C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (02) : 289 - 299
  • [50] Survival Outcomes for Clonal Evolution in Chronic Myeloid Leukemia Patients on Second Generation Tyrosine Kinase Inhibitor Therapy
    Verma, Dushyant
    Kantarjian, Hagop
    Shan, Jianqin
    O'Brien, Susan
    Estrov, Zeev
    Garcia-Manero, Guillermo
    Koller, Charles
    Borthakur, Gautam
    Cortes, Jorge
    CANCER, 2010, 116 (11) : 2673 - 2681
12345